An introductory guide on how to start using CBD hemp oil for your pet. Jun 4, A guide on how to use and dose CBD for your pet. Yes, a small amount of THC in CBD hemp oil is a good thing as it will provide an entourage effect. If you Google search “cbd and pets” right now, the results show three times the like THC and CBD, concentrates and high-CBD/low-THC hemp plants, but only cbd oil or chews, “despite contrary claims,” are illegal for use in pets. “The upper dose limit for CBD products recommended is around 1.
CBD Dosing to Pets Info) for Using Introduction Hemp - Oil CBD School (And
Routine nonsteroidal anti-inflammatory drug NSAID treatments, though efficacious, may not provide adequate relief of pain due to osteoarthritis OA and might have potential side effects that preclude its use, particularly in geriatric patients with certain comorbidities, such as kidney or gastrointestinal pathologies 1 — 4.
Although other pharmacological agents are advocated, such as gabapentin or amantadine, there is little evidence regarding their efficacy in dogs with chronic or neuropathic pain related to OA.
Recent medical interest in alternative therapies and modalities for pain relief has led many pet owners to seek hemp related products rich in cannabinoids. The endocannabinoid receptor system is known to play a role in pain modulation and attenuation of inflammation 5 — 7. Cannabinoid receptors CB1 and CB2 are widely distributed throughout the central and peripheral nervous system 8 — 10 and are also present in the synovium However, the psychotropic effects of certain cannabinoids prevent extensive research into their use as single agents for pain relief 5 , The cannabinoids are a group of as many as 60 different compounds that may or may not act at CB receptors.
One class of cannabinoids, cannabidiol CBD , may actually be an allosteric non-competitive antagonist of CB receptors In lower vertebrates, CBD is also reported to have immunomodulatory 14 , anti-hyperalgesic 15 , 16 , antinociceptive 17 , 18 , and anti-inflammatory actions 5 , 19 , making it an attractive therapeutic option in dogs with OA.
Currently there are several companies distributing nutraceutical derivatives of industrial hemp, rich in cannabinoids for pets, yet little scientific evidence regarding safe and effective oral dosing exists.
The objectives of this study were to determine: Our underlying hypotheses were that appropriate dosing of CBD-rich oil would safely diminish perceived pain and increase activity in dogs with OA. Client owned dogs were enrolled after informed consent in accordance with the Declaration of Helsinki. An initial investigation into single-dose oral pharmacokinetics was performed with 4 beagles 3.
The dogs were fed 2 h after dosing. Physical examination was performed at 0, 4, 8, and 24 h after dosing. Five milliliters of blood was collected at time 0, 0. Blood samples were obtained via jugular venipuncture and transferred to a coagulation tube for 20 min.
CBD was extracted from canine serum using a combination of protein precipitation and liquid-liquid extraction using n-hexane as previously described 20 , with minor modifications for microflow ultra-high pressure liquid chromatography UHPLC. Hexane extract was removed and concentrated to dryness under laboratory nitrogen.
Prior to LC-MS analysis, samples were resuspended in 0. A standard curve using the CBD analytical standard was prepared in canine serum non-exposed to CBD and extracted as above. For this assay, the limits of detection LOD and limits of quantification LOQ represent the lower limits of detection and quantification for each compound in the matrix of this study 23 , Pharmacokinetic variables were estimated by means of non-compartmental analysis, utilizing a pharmacokinetic software package PK Solution, version 2.
The study population consisted of client-owned dogs presenting to Cornell University Hospital for Animals for evaluation and treatment of a lameness due to OA.
Dogs were considered for inclusion in the study if they had radiographic evidence of OA, signs of pain according to assessment by their owners, detectable lameness on visual gait assessment and painful joint s on palpation.
Elevations in alkaline phosphatase ALP , alanine aminotransferase ALT , and aspartate aminotransferase AST were allowed if prior hepatic ultrasound was deemed within normal limits except for potential non-progressive nodules possible hepatic nodular hyperplasia. All owners completed a brief questionnaire to define the affected limb s , duration of lameness, and duration of analgesic or other medications taken.
All dogs underwent radiographic examination of affected joints and a radiologist confirmed the presence or absence of OA, and excluded the presence of concomitant disease that might preclude them from enrolment i.
Other analgesic medications used, such as gabapentin and tramadol, were discontinued at least 2 weeks prior to enrolment. Dogs were excluded if they had evidence of renal, uncontrolled endocrine, neurologic, or neoplastic disease, or were undergoing physical therapy. Every dog was fed its regular diet with no change allowed during the trial. The study was a randomized, placebo-controlled, owner and veterinarian double-blind, cross-over trial.
Dogs received each of two treatments in random order Randomizer iPhone Application: Each treatment was administered for 4 weeks with a 2-week washout period in between treatments. Blood was collected to repeat complete blood counts and chemistry analysis at weeks 2 and 4 for each treatment.
At each visit, each dog was evaluated by a veterinarian based on a scoring system previously reported 25 as well as by its owner canine brief pain inventory [CBPI], Hudson activity scale before treatment initiation and at weeks 2 and 4 thereafter 26 — Initial power analysis was performed to assess number of dogs needed for this study as a cross over design with a power set 0. When calculated it was assumed that 14 dogs would be necessary to find differences in outcomes of interest Statistical analysis was performed with a commercially available software package JMP All continuous data were assessed utilizing a Shapiro—Wilk test for normality.
For ordinal veterinary scoring data a similar linear mixed model was used, but differences from baseline were first calculated to approximate a normal distribution to meet assumptions for a mixed model analysis.
Residual diagnostics of all final models showed that residuals were normally distributed and fulfilled the assumption of homoscedasticity, and assumptions where therefore met.
To control for baseline differences and therefore the possible difference in relative change in CBPI pain, and activity interference assessments and Hudson scoring across dogs, the initial CPBI or Hudson Scores were included for these analyses as a covariate.
Pairwise comparisons between all-time points of both groups were corrected for multiple comparisons with Tukey's post-hoc tests to examine the interaction of time and treatment variables, and to assess differences between change from baseline at any time point as they related to treatment. A p -value of less than 0. Pharmacokinetics demonstrated that CBD half-life of elimination median was 4. Median maximal concentration of CBD oil was Twenty-two client-owned dogs with clinically and radiographically confirmed evidence of osteoarthritis were recruited.
Characteristics of dogs enrolled in a placebo-controlled study investigating the effects of CBD on osteoarthritis.
No other veterinary pain comparisons were statistically significant. Canine Brief Pain Inventory Pain and Activity questions and Hudson Scale mean and standard deviation; lameness, weight-bearing and pain scores median and ranges at each time for cannabidiol CBD and placebo oils.
Chemistry analysis and CBC were performed at each visit. No significant change in the measured CBC values was noted in either the CBD oil or placebo treated dogs data not shown. Other notable significances in serum chemistry values were associated with primarily age or NSAID use.
Box-and-whisker plot of serum alkaline phosphatase ALP activity at each time for treatment and placebo oils. Box represents the mean and 25th and 75th percentile and the whiskers represent the 99th and 1st percentiles. To date, an objective evaluation of the pharmacokinetics of a commercially available industrial hemp product after oral dosing in dogs is absent.
This half-life was shorter than a previous report after intravenous 1. In the intravenous study, CBD distribution was rapid, followed by prolonged elimination with a terminal half-life of 9 h. This may be due to the first pass effect in the liver, and the product was not in an oil base, but a powder within a gelatin capsule being a different delivery vehicle Although our dogs were fasted the delivery vehicle was olive oil which is a food item.
The absorption may be greater and more consistent because of the oil-based vehicle which may be due to the lipophilic nature of CBD, hence delivery with food may be preferable 32 , As previously demonstrated, CBD biotransformation in dogs involves hydroxylation, carboxylation and conjugation, leading to relatively rapid elimination suggesting a more frequent dosing schedule The dosing schedule of twice per day was chosen due to the practical nature of this dosing regimen even though the elimination is well within a three or four time a day dosing regimen.
Our hope was that the lipophilic nature of CBD would allow for a steady state over time, and future studies examining 24 h pharmacokinetics with different dosing regimens with larger numbers of dogs, and steady state serum pharmacokinetics after extended treatment in a clinical population are sorely needed. The main objective of this study was to perform an owner and veterinary double-blinded, placebo-controlled, cross-over study to determine the efficacy of CBD oil in dogs affected by OA.
Additionally, veterinary assessments of pain were also favorable. Although a caregiver placebo effect should be considered with subjective evaluations by owners and veterinarians 35 , the cross-over design limits confounding covariates since each dog serves as its own control. Our statistical model controlled for the possible effect of treatment sequence. The lack of a placebo effect in our study may be due to nine of the 16 owners being intimately involved in veterinary medical care, all of whom have an understanding of the placebo effect making them more cognizant of improvements when providing feedback.
In addition, there was a noticeable decrease in Hudson scores and rise in CBPI scores during the initiation placebo treatment suggesting a potential carry over effect of CBD treatment indicating that a longer washout period might be indicated in future studies. This carry over effect may have resulted in some improved perceptions at the initiation of the placebo treatment which were eliminated by week 4 of placebo treatment, underscoring the importance of longer term steady state PK studies in dogs.
There was no significant difference in subjective veterinary lameness score and weight-bearing capacity throughout the study. Kinetic data was obtained from these dogs data not shown , however 11 of the 16 dogs had significant bilateral disease stifle, coxofemoral, or elbow making evaluation of peak vertical force or symmetry tenuous at best. Unilateral disease in any of the aforementioned joints would be ideal to study the kinetic effects of this or similar extracts for pain relief leading to better objective outcomes.
The population we used in our investigation was representative of dogs presenting in a clinical setting for management of OA and represents the typical OA patient. Currently, NSAIDs are the primary treatment for OA and are associated with negative effects on the gastrointestinal tract and glomerular filtration 2. In the current study, no significant difference was noted in BUN, creatinine, or phosphorus between dogs treated with the CBD oil vs.
A mild rise in creatinine from baseline was noted in both groups at weeks 2 and 4, the hydration status of the dogs was unknown; however changes in albumin sodium, and chloride were unchanged suggesting euhydration, and all creatinine values remained within the reference interval.
Increased ALP activity is fairly sensitive for hepatobiliary changes in this age group, but not specific. Increased ALP activity noted in nine dogs in the CBD treatment group may be an effect of the hemp extract attributed to the induction of cytochrome p mediated oxidative metabolism of the liver reported previously with prolonged exposure to cannabis 36 — Other causes of cholestasis, increased endogenous corticosteroid release from stress, or a progression of regenerative nodular hyperplasia of the liver cannot be ruled out.
Without concurrent significant rise in ALT in the CBD treatment to support hepatocellular damage, or biopsy for further clarification, the significance is uncertain. As such, it may be prudent to monitor liver enzyme values especially ALP while dogs are receiving industrial hemp products until controlled long term safety studies are published.
A recent survey reported that pet owners endorse hemp based treats and products because of perceived improvement in numerous ailments, as hemp products were moderately to very helpful medicinally Some of the conditions thought to be relieved by hemp consumption were: One immunohistochemical study suggested that cannabinoids could protect against the effects of immune-mediated and inflammatory allergic disorders in dogs 40 whereas another uncontrolled study suggested that CBD has anticonvulsant and anti-epileptic properties in dogs There were some dogs with incidental rises in alkaline phosphatase that could be related to the treatment.
Further long-term studies with larger populations are needed to identify long-term effects of CBD rich industrial hemp treatment, however short term effects appear to be positive. L-JG was responsible for data analysis and interpretation, drafting of the manuscript and approval of the submitted manuscript.
JB was responsible for the conception of the study and manuscript writing and revisions. CF was responsible for acquisition of data and manuscript revision. WS was responsible for pharmacokinetic evaluation and revision of the manuscript. SM was responsible for statistical analysis, data analysis and revision of the manuscript. LW was responsible for laboratory work including liquid chromatography-mass spectrometry. The cat thrived and lived two more good years. Since then, I have been a vocal advocate for cannabis-based therapy for animals.
Fortunately, that is changing as we move to legalization and veterinarians are allowed to research cannabis. Several promising clinical trials have been conducted this year looking at the benefits of CBD in dogs with arthritis and dogs with seizure disorders at Cornell University College and Colorado State University. Closer to home, the Veterinary Drug Directorate of Health Canada recently authorized a research study on the effectiveness of CBD to treat anxiety in dogs. The veterinary community has recently become more vocal about the therapeutic implications of cannabis.
As the evidence continues to grow about the benefits of cannabis for companion animals, numerous companies have entered the cannabis-for-pets market. I recently joined one of them True Leaf to bring legal, safe, quality-controlled hemp-seed-based and CBD products for pets to the market.
Pet owners considering administering cannabis to their pet must first consult with their veterinarian. The best option is to start with a hemp-seed-based product which is legally compliant and has negligible CBD and THC content. Until there are other legal and quality-controlled cannabis pet products, pet owners should proceed cautiously. Products should clearly state the cannabinoid potency and should carry a certificate of analysis from the manufacturer identifying all contents, including any residual traces of pesticides, solvents or other contaminants.
I have pledged and dedicated my life to promoting animal health and alleviating animal suffering. The potential of cannabis-based medicine allows veterinarians to do just that and return the love to our beloved pets. This is a space where subscribers can engage with each other and Globe staff.
Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe. If you would like to write a letter to the editor, please forward it to letters globeandmail. Readers can also interact with The Globe on Facebook and Twitter. Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.
Read our community guidelines here. Site navigation Your reading history. Article text size A. To view your reading history, you must be logged in. Contributed to The Globe and Mail.
Published October 17, Updated October 16, Open this photo in gallery. Story continues below advertisement. Follow us on Twitter globedebate Opens in a new window. Log in Subscribe to comment Why do I need to subscribe?
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
CBD, or cannabidiol, is a compound found in cannabis and hemp. While there's no definitive scientific data on using CBD to treat dogs, the Colorado State University's College of Veterinary Medicine and The U.S. Food and Drug Administration has not approved CBD and has not issued a dosing. CBD oil is even becoming popular among pet owners who wish to help their pets live Hemp oil does not contain any CBD or other cannabinoids. CBD Around A.D. 77, the Romans began using hemp extensively in the healing arts. In Chapter 1 we'll discuss some basic information about CBD Oil such as what it is and. The CBD Professor is here to teach you all about the benefits of cannabidiol ( CBD)! Is a little THC OK for Pets? CBD and Epilepsy (Introduction to CBD for Epilepsy) - Duration: 4 minutes, 24 seconds. Can CBD Hemp Oil Work for Epilepsy (As Well As CBD Marijuana Oil)? . (Lower blood sugar by using CBD oil?).